Selection of DNA aptamers for breast cancer

被引：3

作者：

Zamay G.S. ^{[1
,2
]}

Belyanina I.V. ^{[2
]}

Zamay A.S. ^{[2
]}

Komarova M.A. ^{[2
]}

Krat A.V. ^{[3
]}

Eremina E.N. ^{[2
,3
]}

Zukov R.A. ^{[2
,3
]}

Sokolov A.E. ^{[1
]}

Zamay T.N. ^{[1
,2
]}

机构：

[1] Kirensky Institute of Physics, Krasnoyarsk

[2] Voino-Yasenetski Krasnoyarsk State Medical University, ul. Partizana Zheleznyaka 1, Krasnoyarsk

[3] Kryzhanovsky Krasnoyarsk Regional Clinical Cancer Center (KKRCCC), Krasnoyarsk

来源：

Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry | 2016年 / 10卷 / 2期

关键词：

breast cancer; DNA aptamers; oligonucleotides; SELEX;

D O I：

10.1134/S1990750816020128

中图分类号：

学科分类号：

摘要：

A method of selection of DNA aptamers to breast tumor tissue based on the use of postoperative material has been developed. Breast cancer tissues were used as the positive target; the negative targets included benign tumor tissue, adjacent healthy tissues, breast tissues from mastopathy patients, and also tissues of other types of malignant tumors. During selection a pool of DNA aptamers demonstrating selective binding to breast cancer cells and tissues and insignificant binding to breast benign tissues has been obtained. These DNA aptamers can be used for identification of protein markers, breast cancer diagnostics, and targeted delivery of anticancer drugs. © 2016, Pleiades Publishing, Ltd.

引用

页码：158 / 164

页数：6

共 23 条

[11]

Kolovskaya O.S., Savitskaya A.G., Zamay T.N., Reshetneva I.T., Zamay G.S., Erkaev E.N., Wang X.B., Wehbe M.B., Salmina A.B., Perianova O.V., Zubkova O.A., Spivak E.A., Mezko V.S., Glazyrin Y.E., Titova N.M., Berezovski M.V., Zamay A.S., J. Medic. Chem., 56, pp. 1564-1572, (2013)

[12]

Kolovskaya O.S., Zamay T.N., Zamay A.S., Glazyrin Y.E., Spivak E.A., Zubkova O.A., Kadkina A.V., Erkaev E.N., Zamay G.S., Savitskaya A.G., Trufanova L.V., Petrova L.L., Berezovsky M.V., Biochemistry (Moscow) Supplement Series A: Membrane and Cell Biology, 8, pp. 60-72, (2014)

[13]

Zamay A.S., Zamay G.S., Glazyrin Y.E., Zamay T.N., Krat A.V., Modestov A.A., Zubkova O.A., Spivak E.A., Sukhovolskaia M.A., Kuznetsova S.A., Salmina A.B., Gargaun A.A., Berezovski M.V., Kolovskaya O.S., Oligos & Peptides-ChimicaOggi-Chemistry Today, 32, pp. 24-28, (2014)

[14]

Zamay G.S., Kolovskaya O.S., Zamay T.N., Glazyrin Y.E., Krat A.V., Zubkova O., Spivak E., Wehbe M., Gargaun A., Muharemagic D., Komarova M., Grigorieva V., Savchenko A., Modestov A.A., Berezovski M.V., Zamay A.S., Molecular Therapy, 23, pp. 1486-1496, (2015)

[15]

Ruff K.M., Snyder T.M., Liu D.R., J. Amer. Chem. Soc., 132, pp. 9453-9464, (2010)

[16]

Zhang K., Tang L., Sefah K., Zhao Z., Zhu G., Sun W., Goodison S., Tan W., ChemMedChem, 7, pp. 79-84, (2012)

[17]

Li X., Zhang W., Liu L., Zhu Z., Ouyang G., An Y., Zhao C., Yang C.J., Anal. Chem., 86, pp. 6596-6603, (2014)

[18]

Hu Y., Duan J., Zhan Q., Wang F., Lu X., Yang X.-D., PLoS One, 7, (2012)

[19]

Giangrande P., McNamara J., Thiel K., Thiel W., Rockney W., HER2 Nucleaic Acid Aptamers, (2013)

[20]

Lee Y.J., Kim S., Park S.-A., Kim Y., Lee J.E., Noh D.-Y., Kim K.-T., Ryu S.H., Suh P.-G., Molecular Therapy, 21, pp. 1004-1013, (2013)

← 1 2 3 →